AbbVie ABBV-295, an investigational long-acting amylin analog being developed for chronic weight management, has demonstrated favorable tolerability, meaningful body weight reduction and a pharmacokinetic profile supporting less frequent administration in detailed Phase 1 clinical trial results presented at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan, Italy.
On September 30, 2026, AbbVie announced detailed findings from the multiple ascending dose (MAD) portion of its Phase 1 clinical study evaluating ABBV-295 in adults. The findings highlighted an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting further investigation of dosing schedules beyond conventional weekly administration.
The investigational therapy represents a non-incretin-based approach to obesity management, targeting the amylin pathway rather than relying on incretin mechanisms associated with GLP-1 and GIP receptor agonists.
According to AbbVie, the detailed clinical findings support advancing ABBV-295 into Phase 2 development for chronic weight management.
ABBV-295 Phase 1 Study Demonstrates Potential for Less Frequent Dosing
The Phase 1 multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous ABBV-295.
The detailed results presented at EASD 2026 included 60 participants enrolled in Part 2B/2C of the MAD study. Participants were randomized to receive ABBV-295 or placebo, with different dose levels and administration frequencies evaluated over 12 to 13 weeks.
Of the 60 participants, 45 received ABBV-295, while 15 received placebo. The study population had a mean age of 41.5 years and a mean body mass index (BMI) of 29.3 kg/m². Approximately 88% of participants were male.
ABBV-295 was evaluated across different dosing schedules, including weekly administration, every-other-week administration, and monthly administration.
The pharmacokinetic findings demonstrated an approximately 11- to 12-day half-life, alongside dose-proportional increases in plasma exposure.
These findings are relevant to the development strategy for ABBV-295 because they provide a pharmacological basis for evaluating administration intervals longer than once weekly.
AbbVie indicated that the observed pharmacokinetic characteristics support further investigation of every-other-week and monthly dosing regimens.
ABBV-295 Clinical Trial Evaluated Multiple Doses and Administration Schedules
The Phase 1 MAD study investigated ABBV-295 at different dose levels and administration frequencies to characterize its clinical profile.
The evaluated regimens included weekly doses of 4 mg, 6 mg and 14 mg, an every-other-week regimen of 14 mg, and a monthly regimen of 8 mg.
The following table summarizes the study design and participant characteristics reported by AbbVie.
ABBV-295 Phase 1 Multiple Ascending Dose Study Characteristics
| Parameter | Reported Details |
|---|---|
| Company | AbbVie |
| Investigational drug | ABBV-295 |
| Drug classification | Long-acting amylin analog |
| Clinical development stage | Phase 1 |
| Study component | Multiple ascending dose (MAD) |
| Study identification | GUC17-01 |
| Participant population | Adults |
| Total participants in detailed presentation | 60 |
| ABBV-295 treatment group | 45 participants |
| Placebo group | 15 participants |
| Mean participant age | 41.5 years |
| Mean BMI | 29.3 kg/m² |
| Male participants | Approximately 88% |
| Administration route | Subcutaneous |
| Treatment duration | 12–13 weeks |
| Evaluated weekly doses | 4 mg, 6 mg and 14 mg |
| Every-other-week dose | 14 mg |
| Monthly dose | 8 mg |
| Primary evaluation areas | Safety, tolerability, pharmacokinetics and pharmacodynamics |
| Clinical development objective | Chronic weight management |
ABBV-295 Demonstrates Approximately 11–12-Day Half-Life
One of the central findings from the EASD 2026 presentation was the pharmacokinetic profile of ABBV-295.
AbbVie reported an approximately 11- to 12-day half-life, accompanied by dose-proportional increases in plasma exposure.
A longer half-life is an important development characteristic for injectable therapies because it can support the evaluation of less frequent administration schedules.
For ABBV-295, the observed pharmacokinetic profile provides a scientific basis for investigating dosing intervals extending beyond weekly administration.
The company highlighted the potential for both every-other-week and monthly dosing regimens.
However, these schedules remain under clinical evaluation, and the Phase 1 findings do not establish the effectiveness or long-term suitability of monthly administration.
The pharmacokinetic observations will be relevant to subsequent clinical development, particularly when evaluating dose optimization, treatment duration and the relationship between drug exposure and body weight reduction.
ABBV-295 Phase 1 Data Show Meaningful Body Weight Reduction
The detailed EASD 2026 findings build on AbbVie’s earlier announcement of positive topline results from the Phase 1 MAD study in March 2026.
The earlier results demonstrated dose-dependent reductions in body weight across the evaluated treatment groups.
Weekly administration produced least-squares mean body weight reductions ranging from 7.75% to 9.79% at Week 12.
The every-other-week and monthly dosing groups also demonstrated reductions at Week 13.
These findings were observed over a relatively short treatment period of 12 to 13 weeks.
The placebo group demonstrated substantially smaller changes in body weight during the same observation period.
The results provide early clinical evidence supporting continued investigation of ABBV-295 as a potential treatment for chronic weight management.
ABBV-295 Phase 1 Body Weight Reduction Results
| Treatment Group | Administration Schedule | Week 12 Weight Change (LS Mean) | Week 13 Weight Change (LS Mean) |
|---|---|---|---|
| Placebo | Placebo | -0.26% | -0.25% |
| Cohort 3 | Weekly | -7.75% | Not reported |
| Cohort 4 | Weekly | -8.70% | Not reported |
| Cohort 5a | Weekly | -9.79% | Not reported |
| Cohort 5b | Every other week | -7.76% | -9.73% |
| Cohort 6 | Monthly after Week 5 | -6.74% | -7.86% |
ABBV-295 Uses a Non-Incretin Amylin-Based Mechanism
A defining characteristic of ABBV-295 is its mechanism of action.
Unlike incretin-based obesity treatments involving GLP-1 and GIP receptor agonism, ABBV-295 is being developed as a long-acting amylin analog.
Amylin is a satiety hormone involved in regulating appetite and food intake.
According to AbbVie, amylin signaling activates pathways in the brain associated with appetite suppression and reduced food consumption. It also acts as an inhibitory signal that delays gastric emptying.
This biological mechanism provides the scientific rationale for investigating amylin-based therapies in obesity.
ABBV-295 is being developed to activate the amylin pathway through a long-acting injectable formulation.
The approach represents a mechanistically distinct strategy within the broader obesity therapeutics landscape.
Its potential clinical value will depend on the results of subsequent studies evaluating safety, efficacy, dosing schedules and treatment durability.
ABBV-295 Tolerability Findings Support Continued Clinical Development
Alongside pharmacokinetic and body weight findings, ABBV-295 demonstrated a favorable tolerability profile across all evaluated dose levels, according to AbbVie.
The company had previously reported that the Phase 1 MAD study showed no serious adverse events.
The March 2026 topline announcement also identified gastrointestinal disorders as the most commonly reported adverse events. These events were mostly mild and predominantly occurred during the first six weeks of treatment.
The September 2026 detailed presentation reinforced the company’s assessment of the investigational therapy’s tolerability profile.
Tolerability is an important consideration in chronic obesity treatment because therapies intended for long-term administration require evaluation of adverse events throughout extended treatment periods.
Nevertheless, Phase 1 findings provide only an early assessment of safety and tolerability.
Larger clinical studies and longer follow-up will be required to establish the safety profile of ABBV-295.
What ABBV-295 Means for AbbVie’s Obesity Pipeline
The ABBV-295 findings highlight AbbVie’s efforts to investigate therapeutic approaches targeting biological pathways beyond incretin signaling.
The investigational amylin analog combines an early body weight reduction signal with pharmacokinetic characteristics that could support less frequent administration.
The approximately 11- to 12-day half-life is particularly relevant because it supports the scientific evaluation of dosing intervals extending beyond once-weekly treatment.
However, the current evidence remains limited to Phase 1 clinical development, and the reported results should not be interpreted as establishing clinical superiority over existing obesity therapies.
The upcoming clinical development stages will need to determine whether the early findings can be reproduced in larger populations and maintained over longer treatment periods.
For AbbVie, advancing ABBV-295 into Phase 2 would represent the next step in assessing the therapeutic potential of its non-incretin amylin-based approach to chronic weight management.
The EASD 2026 presentation therefore provides an additional clinical foundation for evaluating ABBV-295 as a potential long-acting obesity treatment.
